Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

Joseph B. Domachowske,Yue Chang,Victoria Atanasova,Fernando Cabanas,Kenji Furuno,Kim A. Nguyen, Irfana Banu,Robert J. Kubiak,Amanda Leach,Vaishali S. Mankad, Manish Shroff,Therese Takas,Tonya Villafana, Ulrika Wahlby Hamren

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY（2023）

引用 1|浏览11

暂无评分

摘要

In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease.

查看译文

关键词

monoclonal antibody,nirsevimab,pharmacokinetics,palivizumab,respiratory syncytial virus

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要